BioRestorative Therapies, Inc. (BRTX)
BRTX Stock Price Chart
Explore BioRestorative Therapies, Inc. interactive price chart. Choose custom timeframes to analyze BRTX price movements and trends.
BRTX Company Profile
Discover essential business fundamentals and corporate details for BioRestorative Therapies, Inc. (BRTX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
5 Dec 2012
Employees
11.00
Website
https://www.biorestorative.comCEO
Lance Alstodt
Description
BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. was incorporated in 1997 and is based in Melville, New York.
BRTX Financial Timeline
Browse a chronological timeline of BioRestorative Therapies, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 12 May 2026
Upcoming earnings on 11 Nov 2025
EPS estimate is -$0.38.
Earnings released on 12 Aug 2025
EPS came in at -$0.30 surpassing the estimated -$0.41 by +26.83%, while revenue for the quarter reached $303.30K , missing expectations by -34.07%.
Earnings released on 14 May 2025
EPS came in at -$0.56 falling short of the estimated -$0.32 by -75.00%, while revenue for the quarter reached $25.00K , missing expectations by -93.42%.
Earnings released on 27 Mar 2025
EPS came in at -$0.20 surpassing the estimated -$0.27 by +25.93%, while revenue for the quarter reached $43.30K , missing expectations by -90.88%.
Earnings released on 12 Nov 2024
EPS came in at -$0.13 surpassing the estimated -$0.35 by +62.86%, while revenue for the quarter reached $233.60K , missing expectations by -50.82%.
Earnings released on 13 Aug 2024
EPS came in at -$0.50 surpassing the estimated -$0.56 by +10.71%, while revenue for the quarter reached $89.10K , beating expectations by +791.00%.
Earnings released on 11 Jun 2024
EPS came in at -$0.53 falling short of the estimated -$0.51 by -3.92%, while revenue for the quarter reached $35.00K , beating expectations by +16.67%.
Earnings released on 29 Mar 2024
EPS came in at -$0.57 surpassing the estimated -$0.65 by +12.31%, while revenue for the quarter reached $19.30K , beating expectations by +93.00%.
Earnings released on 13 Nov 2023
EPS came in at -$0.64 surpassing the estimated -$0.68 by +5.88%, while revenue for the quarter reached $30.70K , beating expectations by +2.33%.
Earnings released on 11 Aug 2023
EPS came in at -$0.77 surpassing the estimated -$1.56 by +50.64%, while revenue for the quarter reached $64.50K , beating expectations by +545.00%.
Earnings released on 12 May 2023
EPS came in at -$1.53 falling short of the estimated -$1.26 by -21.43%, while revenue for the quarter reached $31.30K , beating expectations by +0.97%.
Earnings released on 24 Mar 2023
EPS came in at -$1.18 surpassing the estimated -$1.43 by +17.48%, while revenue for the quarter reached $3.70K .
Earnings released on 14 Nov 2022
EPS came in at -$1.28 falling short of the estimated -$0.49 by -161.22%, while revenue for the quarter reached $29.00K .
Earnings released on 15 Aug 2022
EPS came in at -$1.28 falling short of the estimated -$0.55 by -132.73%, while revenue for the quarter reached $71.10K .
Earnings released on 16 May 2022
EPS came in at $1.37 surpassing the estimated -$0.63 by +317.46%, while revenue for the quarter reached $16.00K , missing expectations by -73.38%.
Earnings released on 30 Mar 2022
EPS came in at -$6.90 falling short of the estimated -$0.54 by -1.18K%, while revenue for the quarter reached $5.00K .
Earnings released on 15 Nov 2021
EPS came in at -$4.99 , while revenue for the quarter reached $8.00K .
Stock split effective on 27 Oct 2021
Shares were split 1 : 4000 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 16 Aug 2021
EPS came in at -$4.85 , while revenue for the quarter reached $15.00K .
Earnings released on 17 May 2021
EPS came in at -$19.72 , while revenue for the quarter reached $18.00K .
Earnings released on 29 Apr 2021
EPS came in at -$7.26 , while revenue for the quarter reached $17.00K .
Earnings released on 13 Apr 2021
EPS came in at -$2.10 , while revenue for the quarter reached $15.00K .
Earnings released on 12 Apr 2021
EPS came in at $7.21 , while revenue for the quarter reached $19.00K .
Earnings released on 29 Mar 2021
EPS came in at -$18.94 , while revenue for the quarter reached $26.00K .
Earnings released on 17 Mar 2021
EPS came in at -$3.89 , while revenue for the quarter reached $32.00K .
BRTX Stock Performance
Access detailed BRTX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.